Literature DB >> 3708566

Antitumor activity and biochemical effects of cyclopentenyl cytosine in mice.

J D Moyer, N M Malinowski, S P Treanor, V E Marquez.   

Abstract

Cyclopentenyl cytosine, a recently synthesized inhibitor of cytidine 5'-triphosphate synthesis, has marked antitumor activity. Treatment with 1 mg/kg i.p. on days 1-9 following inoculation with tumor produced 111-122% increased median life span in mice bearing L1210 leukemia, 73-129% increased median life span in mice bearing P388 leukemia, and 58-62% increased median life span in mice with B16 melanoma. A subline of L1210 selected for resistance to 1-beta-D-arabinofuranosylcytosine was more sensitive to cyclopentenyl cytosine than the parent tumor line. L1210 cell growth in cultures was greatly inhibited (greater than 90%) by 0.1 microM cyclopentenyl cytosine, but cells were protected from the growth inhibitory effects by cytidine (20 microM) and to a lesser extent by uridine or deoxycytidine. Exposure of cultured L1210 cells to 1 microM cyclopentenyl cytosine inhibited formation of [3H]cytidine nucleotides from [3H]uridine by 30% during the first 15 min of exposure to drug and by greater than 95% after 2 h of exposure. Treatment of mice bearing L1210 ascites with cyclopentenyl cytosine (1 mg/kg) produced rapid depletion of cytidine nucleotide pools in the tumor cells; these pools fell to 35% of control within 30 min. The effects of cyclopentenyl cytosine on nucleotide pools were tissue selective; the cytidine nucleotide pools of spleen, liver, kidney, and intestine were less sensitive than that of the L1210 ascites tumor. Cytidine nucleotide pools of spleen and liver were depleted by higher doses (10 mg/kg) of cyclopentenyl cytosine.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3708566

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  CTP synthase 1, a smooth muscle-sensitive therapeutic target for effective vascular repair.

Authors:  Rui Tang; Xiao-Bing Cui; Jia-Ning Wang; Shi-You Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-09-05       Impact factor: 8.311

2.  Cyclopentenyl cytosine: interspecies predictions based on rodent plasma and urine kinetics.

Authors:  D S Zaharko; J A Kelley; J E Tomaszewski; L Hegedus; N R Hartman
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

3.  In vitro characterization of the myelotoxicity of cyclopentenyl cytosine.

Authors:  D A Volpe; D L Du; C K Grieshaber; M J Murphy
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Phase I clinical trial of continuous infusion cyclopentenyl cytosine.

Authors:  P M Politi; F Xie; W Dahut; H Ford; J A Kelley; A Bastian; A Setser; C J Allegra; A P Chen; J M Hamilton
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  The pyrimidin analogue cyclopentenyl cytosine induces alloantigen-specific non-responsiveness of human T lymphocytes.

Authors:  N Nikolaeva; F J Bemelman; S-L Yong; A Verschuur; R A W van Lier; I J M ten Berge
Journal:  Clin Exp Immunol       Date:  2007-12-06       Impact factor: 4.330

6.  Identification of critical host mitochondrion-associated genes during Ehrlichia chaffeensis infections.

Authors:  Tonia Von Ohlen; Alison Luce-Fedrow; M Teresa Ortega; Roman R Ganta; Stephen K Chapes
Journal:  Infect Immun       Date:  2012-07-30       Impact factor: 3.441

7.  Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells.

Authors:  C van Bree; Hm Rodermond; R Leen; Jp Medema; Abp van Kuilenburg
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

8.  Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine.

Authors:  E De Clercq; R Bernaerts; Y F Shealy; J A Montgomery
Journal:  Biochem Pharmacol       Date:  1990-01-15       Impact factor: 5.858

9.  Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase.

Authors:  E De Clercq; J Murase; V E Marquez
Journal:  Biochem Pharmacol       Date:  1991-06-15       Impact factor: 5.858

Review 10.  Re-Discovery of Pyrimidine Salvage as Target in Cancer Therapy.

Authors:  Melanie Walter; Patrick Herr
Journal:  Cells       Date:  2022-02-20       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.